We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+45.38%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$22.7B
AUM Growth
+$6.43B
Cap. Flow
-$298M
Cap. Flow %
-1.32%
Top 10 Hldgs %
85.22%
Holding
124
New
14
Increased
20
Reduced
17
Closed
10

Top Buys

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$116M
2
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$86.7M
3
ADCT icon
ADC Therapeutics
ADCT
+$64M
4
NVTA
Invitae Corporation
NVTA
+$48M
5
SYRE icon
Spyre Therapeutics
SYRE
+$20.3M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$416M
2
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$101M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$51.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$36.8M
5
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$23.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.74%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
51
Xencor
XNCR
$1.44B
$13.9M 0.06%
428,120
– –
IMMU
52
DELISTED
Immunomedics Inc
IMMU
$11.7M 0.05%
330,000
+20,000
+6% +$585K
ANAB icon
53
AnaptysBio
ANAB
$1.52B
$11.5M 0.05%
513,677
+279,085
+119% +$5.1M
MIRM icon
54
Mirum Pharmaceuticals
MIRM
$6.66B
$11.4M 0.05%
583,333
– –
AIMT
55
DELISTED
Aimmune Therapeutics
AIMT
$11.3M 0.05%
673,908
– –
HZNP
56
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$11.1M 0.05%
200,000
– –
QURE icon
57
uniQure
QURE
$2.73B
$10.4M 0.05%
230,883
-126,200
-35% -$7.45M
XENE icon
58
Xenon Pharmaceuticals
XENE
$6.2B
$10M 0.04%
+799,102
New +$10.2M
UROV
59
DELISTED
Urovant Sciences Ltd.
UROV
$9.84M 0.04%
1,000,000
– –
ALBO
60
DELISTED
Albireo Pharma Inc
ALBO
$9.78M 0.04%
369,047
– –
KRTX
61
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$9.14M 0.04%
81,976
+40,000
+95% +$3.48M
FLGT icon
62
Fulgent Genetics
FLGT
$559M
$9.11M 0.04%
569,444
– –
SGMO
63
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$8.96M 0.04%
999,823
– –
RETA
64
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$8.73M 0.04%
55,983
– –
ISEE
65
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$8.34M 0.04%
1,635,501
– –
ACGN
66
DELISTED
Aceragen Inc
ACGN
$8.25M 0.04%
271,376
– –
HOOK
67
DELISTED
HOOKIPA Pharma
HOOK
$8.14M 0.04%
70,048
– –
AUTL
68
Autolus Therapeutics
AUTL
$381M
$7.79M 0.03%
485,624
+328,851
+210% +$3.65M
PASG icon
69
Passage Bio
PASG
$14.3M
$7.52M 0.03%
13,750
– –
SYRS
70
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$7.36M 0.03%
69,017
– –
CABA icon
71
Cabaletta Bio
CABA
$437M
$7.09M 0.03%
636,363
– –
ALEC icon
72
Alector
ALEC
$170M
$6.84M 0.03%
280,000
– –
BNR
73
Burning Rock Biotech
BNR
$94M
$6.75M 0.03%
+25,000
New +$6.85M
TARA icon
74
Protara Therapeutics
TARA
$217M
$5.85M 0.03%
199,671
– –
LEGN icon
75
Legend Biotech
LEGN
$3.66B
$5.75M 0.03%
+135,000
New +$5.27M
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2020 Portfolio in Review

As of Q2 2020, Baker Bros. Advisors held 124 positions worth $22.7B, up 40% from $16.2B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Baker Bros. Advisors's Q2 2020 filing shows 14 new, 20 increased, 17 reduced and 10 closed positions. Its largest new stake was Forma Therapeutics Holdings, Inc. Common Stock: 2,000,000 shares worth $93M. The largest sale was Seagen Inc. Common Stock, an estimated $416M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 2,000,000 shares worth $93M.
  • Baker Bros. Advisors added most to MyoKardia, Inc. Common Stock in Q2 2020, an estimated $116M increase.
  • Baker Bros. Advisors's biggest Q2 2020 reduction was Seagen Inc. Common Stock, cutting an estimated $416M.
  • Baker Bros. Advisors fully exited Ra Pharmaceuticals, Inc. Common Stock in Q2 2020, selling an estimated $101M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $22.7B portfolio in Q2 2020.
  • Baker Bros. Advisors opened 14 new positions and closed 10 in Q2 2020.
  • Baker Bros. Advisors's portfolio value rose 40% quarter-over-quarter to $22.7B.

Based on Baker Bros. Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.